

USSN 09/554,533  
Atty Docket No. 238/086US**IN THE SPECIFICATION:**

Please amend the **specification** as follows:

**Page 1, last paragraph (bridging pages 1 and 2) beginning at line 24: Please replace the paragraph with the following:**

The extendins are peptides that are found in venom of the Gila-monster, a lizard endogenous to Arizona and Northern Mexico. Exendin-3 ~~{SEQ ID NO: 1}~~ (SEQ ID NO: 1) is present in the venom of *Heloderma horridum*, and exendin-4 ~~{SEQ ID NO: 2}~~ (SEQ ID NO: 2) is present in the venom of *Heloderma suspectum* (Eng, J., et al., ~~J. Biol. Chem.~~ *J. Biol. Chem.*, 265:20259-62, 1990; Eng[[.]], J., et al., ~~J. Biol. Chem.~~ *J. Biol. Chem.*, 267:7402-05, 1992). The amino acid sequence of exendin-3 is shown in Figure 1. The amino acid sequence of exendin-4 is shown in Figure 2. The extendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1[7-36]NH<sub>2</sub> ~~{SEQ ID NO: 3}~~ (SEQ ID NO: 3) (Goke, et al., ~~J. Biol. Chem.~~ *J. Biol. Chem.*, 268:19650-55, 1993). GLP-1[7-36]NH<sub>2</sub>, also known as proglucagon[78-107] or simply "GLP-1" as used most often herein, has an insulintropic effect, stimulating insulin secretion from pancreatic  $\beta$ -cells; GLP-1 also inhibits glucagon secretion from pancreatic  $\alpha$ -cells (Ørsov, et al., *Diabetes Diabetes*, 42:658-61, 1993; D'Alessio, et al., ~~J. Clin. Invest.~~ *J. Clin. Invest.*, 97:133-38, 1996). The amino acid sequence of GLP-1 is shown in Figure 3. GLP-1 is reported to inhibit gastric emptying (Willms B, et al., ~~J. Clin. Endocrinol. Metab.~~ *J. Clin. Endocrinol. Metab.*, 81(1):327-32, 1996; Wettergren A, et al., ~~Dig. Dis. Sci.~~ *Dig. Dis. Sci.*, 38(4):665-73, 1993), and gastric acid secretion. Schjoldager BT, et al., ~~Dig. Dis. Sci.~~ *Dig. Dis. Sci.*, 34(5):703-8, 1989; O'Halloran DJ, et al., ~~J. Endocrinol.~~ *J. Endocrinol.*, 126(1):169-173, 1990; Wettergren A, et al., ~~Dig. Dis. Sci.~~ *Dig. Dis. Sci.*, 38(4):665-73, 1993). GLP-1[7-37], which has an additional glycine residue at its carboxy terminus, also stimulates insulin secretion in humans (Ørsov, et al., *Diabetes Diabetes*, 42:658-61, 1993).

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 4, fourth full paragraph (lines 24-33): Please replace the paragraph with the following:**

Novel exendin agonist compounds are described in PCT Application Serial No. PCT/US98/16387 filed August 6, 1998, entitled "Novel Exendin Agonist Compounds," claiming the benefit of U.S. Provisional Application Serial No. 60/055,404, filed August 8, 1997. Other novel exendin agonist compounds are described in PCT Application Serial No. [[\_\_\_\_\_]] PCT/US98/24210 filed November 13, 1998, entitled "Novel Exendin Agonist Compounds," which claims the benefit of U.S. Provisional Application No. 60/066,029 filed November 14, 1997.

**Page 5, second paragraph (lines 6-7): Please replace the paragraph with the following:**

According to the present invention, provided are compounds of the formula (I) ~~{SEQ. ID. NO. 4}~~ (SEQ ID NO: 4):

**Page 7, first paragraph (lines 1-8): Please replace the paragraph with the following:**

Also within the scope of the present invention are narrower genera of compounds having peptides of various lengths, for example genera of compounds which do not include peptides having a length of 28, 29 or 30 amino acid residues, respectively. Additionally, the present invention includes narrower genera of compounds having particular amino acid sequences, for example, compounds of the formula (I) ~~{SEQ. ID. NO. 4}~~ (SEQ ID NO: 4):

**Page 8, last full paragraph (lines 29-30): Please replace the paragraph with the following:**

Also provided are compounds of the formula (II) ~~{SEQ. ID. NO. 66}~~ (SEQ ID NO: 66):

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 11, third paragraph (lines 11-15): Please replace the paragraph with the following:**

Preferred compounds of formula (II) include those wherein  $X_1$  is Lys, Asn, Lys-NH<sup>6</sup>-R Asn, or Lys-NH<sup>6</sup>-R Ala where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl. Especially preferred compounds of formula (II) include Compound Nos. 62-69 ~~{SEQ. ID. NOS. 67-74}~~ (SEQ ID NOS: 67-74).

**Pages 14-15, section titled "Brief Description of the Drawings" (page 14, line 8, through page 15, line 3): Please replace the section with the following:**

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the amino acid sequence for exendin-3 ~~{SEQ. ID. NO. 1}~~ (SEQ ID NO: 1).

Figure 2 depicts the amino acid sequence for exendin-4 ~~{SEQ. ID. NO. 2}~~ (SEQ ID NO: 2).

Figure 3 depicts the amino acid sequence for GLP-1[7-36]NH<sub>2</sub> (GLP-1) ~~{SEQ. ID. NO. 3}~~ (SEQ ID NO: 3).

~~Figure 4 depicts~~ Figures 4A-4B depict the amino acid sequences for certain compounds of the present invention, Compounds 1-61 ~~{SEQ. ID. NOS. 5 to 65}~~ (SEQ ID NOS: 5-65).

Figure 5 depicts the effect on lowering blood glucose of various concentrations of Compound 3 ~~{SEQ. ID. NO. 7}~~ (SEQ ID NO: 7).

Figure 6 depicts the effect on gastric emptying of various concentrations of Compound 2 ~~{SEQ. ID. NO. 6}~~ (SEQ ID NO: 6).

Figure 7 depicts a comparison of effects on gastric emptying of various concentrations of Compound 3 ~~{SEQ. ID. NO. 7}~~ (SEQ ID NO: 7).

Figure 8 depicts a comparison of effects on gastric emptying of various concentrations of Compound 10 ~~{SEQ. ID. NO. 14}~~ (SEQ ID NO: 14).

Figure 9 depicts a comparison of effects on gastric emptying of various concentrations of Compound 13 ~~{SEQ. ID. NO. 17}~~ (SEQ ID NO: 17).

Figure 10 depicts the amino acid sequences for certain compounds of the present invention, Compound Nos. 62 - 69 ~~{SEQ. ID. NOS. 67 - 74}~~ (SEQ ID NOS: 67-74).

USSN 09/554,533  
 Atty Docket No. 238/086US

**Page 15, second full paragraph (lines 5-6): Please replace the paragraph with the following:**

According to the present invention, provided are compounds of the formula (I) ~~{SEQ. ID. NO. 4}~~ (SEQ ID NO: 4):

**Page 16, last paragraph (bridging pages 16 and 17) beginning at line 32: Please replace the paragraph with the following:**

Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms. Suitable compounds of formula (I) include those identified in Examples 1-61 ("Compounds 1-61," respectively) ~~{SEQ. ID. NOS. 5 to 65}~~ (SEQ ID NOS: 5-65), as well as those corresponding compounds identified in Examples 70 and 71.

**Page 17, last paragraph (bridging pages 17 and 18) beginning at line 29: Please replace the paragraph with the following:**

According to an especially preferred aspect, especially preferred compounds include those of formula (I) wherein: Xaa<sub>1</sub> is His or Arg; Xaa<sub>2</sub> is Gly or Ala; Xaa<sub>3</sub> is Asp or Glu; Xaa<sub>4</sub> is Ala or Thr; Xaa<sub>5</sub> is Ala, Phe or ~~naphthylalanine~~ naphthylalanine; Xaa<sub>7</sub> is Thr or Ser; Xaa<sub>8</sub> is Ala, Ser or Thr; Xaa<sub>9</sub> is Asp or Glu; Xaa<sub>10</sub> is Ala, Leu or pentylglycine; Xaa<sub>11</sub> is Ala or Ser; Xaa<sub>12</sub> is Ala or Lys; Xaa<sub>13</sub> is Ala or Gln; Xaa<sub>14</sub> is Ala, Leu or pentylglycine; Xaa<sub>15</sub> is Ala or Glu; Xaa<sub>16</sub> is Ala or Glu; Xaa<sub>17</sub> is Ala or Glu; Xaa<sub>19</sub> is Ala or Val; Xaa<sub>20</sub> is Ala or Arg; Xaa<sub>21</sub> is Ala or Leu; Xaa<sub>22</sub> is Phe or naphthylalanine; Xaa<sub>23</sub> is Ile, Val or tert-butylglycine; Xaa<sub>24</sub> is Ala, Glu or Asp; Xaa<sub>25</sub> is Ala, Trp or Phe; Xaa<sub>26</sub> is Ala or Leu; Xaa<sub>27</sub> is Ala or Lys; Xaa<sub>28</sub> is Ala or Asn; Z<sub>1</sub> is -OH, -NH<sub>2</sub>, Gly-Z<sub>2</sub>, Gly Gly-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub> Ser-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub> Ser Ser-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub> Ser Ser Gly-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub>-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub> Ser Ser Gly Ala Xaa<sub>36</sub> Xaa<sub>37</sub> Xaa<sub>38</sub>-Z<sub>2</sub>; Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37</sub> and Xaa<sub>38</sub> being independently Pro homoproline, thioproline or N-methylalanine; and Z<sub>2</sub> being -OH or -NH<sub>2</sub>; provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, Xaa<sub>27</sub> and Xaa<sub>28</sub> are Ala. Especially preferred compounds of formula

USSN 09/554,533  
Atty Docket No. 238/086US

(I) include those having the amino acid sequence of ~~SEQ. ID. NOS. 6-27~~ SEQ ID NOS: 6-27 (Compounds 2-23).

**Page 18, last paragraph (bridging pages 18 and 19) beginning at line 28: Please replace the paragraph with the following:**

Also within the scope of the present invention are narrower genera of compounds having peptides of various lengths, for example genera of compounds which do not include peptides having a length of 28, 29 or 30 amino acid residues, respectively. Additionally, the present invention includes narrower genera of compounds having particular amino acid sequences, for example, compounds of the formula (I) ~~[SEQ. ID. NO. 4]~~ (SEQ ID NO: 4):

**Page 20, first full paragraph (lines 23-24): Please replace the paragraph with the following:**

Also provided are compounds of the formula (II) ~~[SEQ. ID. NO. 66]~~ (SEQ ID NO: 66):

**Page 23, first full paragraph (lines 6-10): Please replace the paragraph with the following:**

Preferred compounds of formula (II) include those wherein  $X_1$  is Lys Asn, Lys-NH<sup>6</sup>-R Asn, or Lys-NH<sup>6</sup>-R Ala where R is Lys, Arg, C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkanoyl. Preferred compounds of formula (II) include Compound Nos. 62-69 ~~[SEQ. ID. NOS. 67-74]~~ (SEQ ID NOS: 67-74).

**Page 31, third full paragraph (lines 21-23): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH<sub>2</sub> ~~[SEQ. ID. NO. 5]~~ (SEQ ID NO: 5)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 32, last full paragraph (lines 26-28): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 6~~] (SEQ ID NO: 6)

**Page 33, second paragraph (lines 14-16): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 7~~] (SEQ ID NO: 7)

**Page 34, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 8~~] (SEQ ID NO: 8)

**Page 34, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 9~~] (SEQ ID NO: 9)

**Page 35, first full paragraph (lines 10-12): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Ala Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 10~~] (SEQ ID NO: 10)

**Page 36, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 11~~] (SEQ ID NO: 11)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 36, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 12~~] (SEQ ID NO: 12)

**Page 37, first full paragraph (lines 9-11): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 13~~] (SEQ ID NO: 13)

**Page 37, last paragraph (bridging pages 37 and 38) beginning at line 25: Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 14~~] (SEQ ID NO: 14)

**Page 38, second full paragraph (lines 15-17): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 15~~] (SEQ ID NO: 15)

**Page 39, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 16~~] (SEQ ID NO: 16)

**Page 39, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Ala Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 17~~] (SEQ ID NO: 17)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 40, first full paragraph (lines 10-12): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Ala Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 18~~] (SEQ ID NO: 18)

**Page 41, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Ala Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 19~~] (SEQ ID NO: 19)

**Page 41, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Ala Arg  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 20~~] (SEQ ID NO: 20)

**Page 42, first full paragraph (lines 9-11): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Ala  
Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 21~~] (SEQ ID NO: 21)

**Page 42, last paragraph (bridging pages 42 and 43) beginning at line 25: Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Ala Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 22~~] (SEQ ID NO: 22)

**Page 43, second full paragraph (lines 15-17): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Ala Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 23~~] (SEQ ID NO: 23)



USSN 09/554,533  
Atty Docket No. 238/086US

**Page 44, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Ala Leu Lys Asn-NH<sub>2</sub> ~~{SEQ. ID. NO. 24}~~ (SEQ ID NO: 24)

**Page 44, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Ala Lys Asn-NH<sub>2</sub> ~~{SEQ. ID. NO. 25}~~ (SEQ ID NO: 25)

**Page 45, first full paragraph (lines 10-12): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Ala Asn-NH<sub>2</sub> ~~{SEQ. ID. NO. 26}~~ (SEQ ID NO: 26)

**Page 46, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Ala-NH<sub>2</sub> ~~{SEQ. ID. NO. 27}~~ (SEQ ID NO: 27)

**Page 46, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH<sub>2</sub> ~~{SEQ. ID. NO. 28}~~ (SEQ ID NO: 28)

**Page 47, first full paragraph (lines 9-11): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH<sub>2</sub> ~~{SEQ. ID. NO. 29}~~ (SEQ ID NO: 29)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 47, last paragraph (bridging pages 47 and 48) beginning at line 25): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH<sub>2</sub> {~~SEQ. ID. NO. 30~~}  
(SEQ. ID. NO. 30)

**Page 48, second full paragraph (lines 15-17): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH<sub>2</sub> {~~SEQ. ID. NO. 31~~}  
(SEQ. ID. NO. 31)

**Page 49, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH<sub>2</sub> {~~SEQ. ID. NO. 32~~}  
(SEQ. ID. NO. 32)

**Page 49, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH<sub>2</sub> {~~SEQ. ID. NO. 33~~}  
(SEQ. ID. NO. 33)

**Page 50, first full paragraph (lines 10-12): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH<sub>2</sub> {~~SEQ. ID. NO. 34~~} (SEQ. ID. NO. 34)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 51, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH<sub>2</sub> [~~SEQ. ID. NO. 35~~] (SEQ ID  
NO: 35)

**Page 51, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly-NH<sub>2</sub> [~~SEQ. ID. NO. 36~~] (SEQ ID  
NO: 36)

**Page 52, first full paragraph (lines 9-11): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly-NH<sub>2</sub> [~~SEQ. ID. NO. 37~~] (SEQ ID  
NO: 37)

**Page 52, last paragraph (bridging pages 52 and 53) beginning at line 25: Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser-NH<sub>2</sub> [~~SEQ. ID. NO. 38~~] (SEQ ID NO: 38)

**Page 53, second full paragraph (lines 15-17): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser-NH<sub>2</sub> [~~SEQ. ID. NO. 39~~] (SEQ ID  
NO: 39)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 54, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser-NH<sub>2</sub> ~~{SEQ. ID. NO. 40}~~ (SEQ ID NO: 40)

**Page 54, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser-NH<sub>2</sub> ~~{SEQ. ID. NO. 41}~~ (SEQ ID NO: 41)

**Page 55, first full paragraph (lines 10-12): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro-NH<sub>2</sub> ~~{SEQ. ID. NO. 42}~~ (SEQ ID NO: 42)

**Page 56, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro-NH<sub>2</sub> ~~{SEQ. ID. NO. 43}~~ (SEQ ID NO: 43)

**Page 56, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly-NH<sub>2</sub> ~~{SEQ. ID. NO. 44}~~ (SEQ ID NO: 44)

**Page 57, first full paragraph (lines 9-11): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly-NH<sub>2</sub> ~~{SEQ. ID. NO. 45}~~ (SEQ ID NO: 45)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 57, last paragraph (bridging pages 57 and 58) beginning at line 25: Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly-NH<sub>2</sub> [~~SEQ ID NO: 46~~] (SEQ ID NO: 46)

**Page 58, second full paragraph (lines 15-17): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly tPro Ser Ser Gly Ala tPro tPro tPro-NH<sub>2</sub> [~~SEQ ID NO: 47~~] (SEQ ID NO: 47)

**Page 59, first full paragraph (lines 4-6): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala tPro tPro tPro-NH<sub>2</sub> [~~SEQ ID NO: 48~~] (SEQ ID NO: 48)

**Page 59, third full paragraph (lines 21-23): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly NMeala Ser Ser Gly Ala Pro Pro-NH<sub>2</sub> [~~SEQ ID NO: 49~~] (SEQ ID NO: 49)

**Page 60, first full paragraph (lines 13-15): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly NMeala Ser Ser Gly Ala NMeala NMeala-NH<sub>2</sub> [~~SEQ ID NO: 50~~] (SEQ ID NO: 50)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 61, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro-NH<sub>2</sub> {~~SEQ ID NO: 54~~} (SEQ ID NO: 51)

**Page 61, third full paragraph (lines 20-22): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro-NH<sub>2</sub> {~~SEQ ID NO: 52~~} (SEQ ID NO: 52)

**Page 62, first full paragraph (lines 11-13): Please replace the paragraph with the following:**

Arg Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH<sub>2</sub> {~~SEQ ID NO: 53~~} (SEQ ID NO: 53)

**Page 63, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH<sub>2</sub> {~~SEQ ID NO: 54~~} (SEQ ID NO: 54)

**Page 63, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Naphthylala Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val  
Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> {~~SEQ ID NO: 55~~} (SEQ ID NO: 55)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 64, first full paragraph (lines 9-11): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn-NH<sub>2</sub> [~~SEQ-ID-NO-56~~] (SEQ ID NO: 56)

**Page 64, last paragraph (bridging pages 64 and 65) beginning at line 25: Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Ser Thr Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn-NH<sub>2</sub> [~~SEQ-ID-NO-57~~] (SEQ ID NO: 57)

**Page 65, second full paragraph (lines 15-17): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Met Ala Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn-NH<sub>2</sub> [~~SEQ-ID-NO-58~~] (SEQ ID NO: 58)

**Page 66, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp pentylgly Ser Lys Gln Leu Glu Glu Glu Ala Val  
Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ-ID-NO-59~~] (SEQ ID NO: 59)

**Page 66, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Naphthylala Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ-ID-NO-60~~] (SEQ ID NO: 60)

**Page 67, first full paragraph (lines 10-12): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe tButylgly Glu Trp Leu Lys Asn-NH<sub>2</sub> [~~SEQ-ID-NO-61~~] (SEQ ID NO: 61)

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 68, first full paragraph (lines 3-5): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Asp Phe Leu Lys Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 62~~] (SEQ ID NO: 62)

**Page 68, third full paragraph (lines 19-21): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser-NH<sub>2</sub> [~~SEQ. ID. NO. 63~~] (SEQ ID NO: 53)

**Page 69, first full paragraph (lines 9-11): Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly-NH<sub>2</sub> [~~SEQ. ID. NO. 64~~] (SEQ ID NO: 64)

**Page 69, last paragraph (bridging pages 69 and 70) beginning at line 25: Please replace the paragraph with the following:**

His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met Glu Glu Glu Ala Val Arg  
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro hPro-NH<sub>2</sub> [~~SEQ. ID. NO. 65~~] (SEQ ID NO: 65)

**Page 70, last paragraph (bridging pages 70 and 71) beginning at line 16: Please replace the paragraph with the following:**

Compound 62, 4-imidazolylpropionyl-Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys-NH<sup>6</sup>octanoyl Asn-NH<sub>2</sub> [~~SEQ. ID. NO. 67~~] (SEQ ID NO: 67), is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxymethyl acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Fmoc-Lys-NH<sup>6</sup>octanoyl acid is used for coupling at position 27. In-



USSN 09/554,533  
Atty Docket No. 238/086US

stead of using a protected amino acid for the final coupling at position 1, 4-imidazolylpropionic acid is coupled directly to the N-terminus of residues 2-28 on the resin. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3405.0

**Page 71, first full paragraph (lines 7-24): Please replace the paragraph with the following:**

Compound 63, 4-imidazolylpropionyl-Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys-NH<sup>ε</sup>octanoyl Asn-NH<sub>2</sub> ~~{SEQ ID NO: 68}~~ (SEQ ID NO: 68), is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Fmoc-Lys-NH<sup>ε</sup>octanoyl acid is used for coupling at position 27. Instead of using a protected amino acid for the final coupling at position 1, 4-imidazolylpropionic acid is coupled directly to the N-terminus of residues 2-28 on the resin. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3347.9

**Page 71, last paragraph (bridging pages 71 and 72) beginning at line 27: Please replace the paragraph with the following:**

Compound 64, 4-imidazolylpropionyl-Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys-NH<sup>ε</sup>octanoyl Asn Gly Gly-NH<sub>2</sub> ~~{SEQ ID NO: 69}~~ (SEQ ID NO: 69) assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Fmoc-Lys-NH<sup>ε</sup>octanoyl acid is used for coupling at position 27. Instead of using a protected amino acid for the final coupling at position 1, 4-imidazolylpro-

USSN 09/554,533  
Atty Docket No. 238/086US

pionic acid is coupled directly to the N-terminus of residues 2-30 on the resin. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3519.0

**Page 72, last paragraph (bridging pages 72 and 73) beginning at line 20: Please replace the paragraph with the following:**

Compound 65, 4-imidazolylpropionyl-Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys-NH<sup>o</sup>octanoyl Asn Gly Gly-NH<sub>2</sub> ~~{SEQ ID NO: 70}~~ (SEQ ID NO: 70), is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Fmoc-Lys-NH<sup>o</sup>octanoyl acid is used for coupling at position 27. Instead of using a protected amino acid for the final coupling at position 1, 4-imidazolylpropionic acid is coupled directly to the N-terminus of residues 2-30 on the resin. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3451.9

**Page 73, last paragraph (lines 11-28): Please replace the paragraph with the following:**

Compound 66, 4-imidazolylpropionyl-Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Asn Lys-NH<sup>o</sup>octanoyl-NH<sub>2</sub> ~~{SEQ ID NO: 71}~~ (SEQ ID NO: 71), is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Fmoc-Lys-NH<sup>o</sup>octanoyl acid is used for the initial coupling onto the resin at position 28. Instead of using a protected amino acid for the final coupling at position 1, 4-imidazolylpropionic acid is coupled directly to the N-terminus of protected residues 2-28 on

USSN 09/554,533  
Atty Docket No. 238/086US

the resin. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3405.0

**Page 74, first full paragraph (lines 3-20): Please replace the paragraph with the following:**

Compound 67, 4-imidazolylpropionyl-Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Asn Lys-NH<sup>6</sup>octanoyl-NH<sub>2</sub> [~~SEQ. ID. NO. 72~~], (SEQ ID NO: 72), is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Fmoc-Lys-NH<sup>6</sup>octanoyl acid is used for the initial coupling onto the resin at position 28. Instead of using a protected amino acid for the final coupling at position 1, 4-imidazolylpropionic acid is coupled directly to the N-terminus of residues 2-28 on the resin. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3347.9

**Page 74, last paragraph (bridging pages 74 and 75) beginning at line 23: Please replace the paragraph with the following:**

Compound 68, 4-imidazolylpropionyl-Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Asn Lys-NH<sup>6</sup>octanoyl Gly Gly-NH<sub>2</sub> [~~SEQ. ID. NO. 73~~], (SEQ ID NO: 73), is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Fmoc-Lys-NH<sup>6</sup>octanoyl acid is used for coupling at position 28. Instead of using a protected amino acid for the final coupling at position 1, 4-imidazolylpropionic acid is coupled directly to the N-terminus of protected residues 2-30 on the resin. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-

USPN 09/554,533  
Att. Docket No. 238/086US

HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3519.0

**Page 75, last paragraph (bridging pages 75 and 76) beginning at line 16: Please replace the paragraph with the following:**

Compound 69, 4-imidazolylpropionyl-Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Asn Lys-NH<sup>6</sup>octanoyl Gly Gly-NH<sub>2</sub> [~~SEQ. ID. NO. 74~~], (SEQ ID NO: 74), is assembled on 4-(2'-4'-dimethoxyphenyl)-Fmoc amino-methyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 1. Fmoc-Lys-NH<sup>6</sup>octanoyl acid is used for coupling at position 28. Instead of using a protected amino acid for the final coupling at position 1, 4-imidazolylpropionic acid is coupled directly to the N-terminus of residues 2-30 on the resin. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3451.9

**Page 76, first full paragraph (lines 9-20): Please replace the paragraph with the following:**

Compounds 1-23, 30-37, 40-42, 49-58 and 62-69 [~~SEQ. ID. NOS. 5-27, 34-41, 44-46, 53-62 and 67-74~~] (SEQ ID NOS: 5-27, 34-41, 44-46, 53-62 and 67-74) are assembled on the so called Wang resin (p-alkoxybenzylalcohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).

USSN 09/554,533  
Atty Docket No. 238/086US

**Page 76, last paragraph (bridging pages 76 and 77) beginning at line 25: Please replace the paragraph with the following:**

Compounds 24-29, 38, 39, and 43-48 [~~SEQ. ID. NOS. 28-33, 42, 43 and 47-52~~] (SEQ ID NOS: 28-33, 42, 43 and 47-52) are assembled on the 2-chlorotriylchloride resin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).

**Page 79, Table I (lines 1-26): Please replace Table I with the following:**

**TABLE I**

<u>Compound</u>	<u>IC<sub>50</sub> (nM)</u>
Exendin-4 [ <del>SEQ. ID. NO. 2</del> ] ( <u>SEQ ID NO: 2</u> )	0.70
Compound 1 [ <del>SEQ. ID. NO. 5</del> ] ( <u>SEQ ID NO: 5</u> )	0.67
Compound 2 [ <del>SEQ. ID. NO. 6</del> ] ( <u>SEQ ID NO: 6</u> )	1.21
Compound 3 [ <del>SEQ. ID. NO. 7</del> ] ( <u>SEQ ID NO: 7</u> )	0.67
Compound 4 [ <del>SEQ. ID. NO. 8</del> ] ( <u>SEQ ID NO: 8</u> )	0.42
Compound 5 [ <del>SEQ. ID. NO. 9</del> ] ( <u>SEQ ID NO: 9</u> )	1.91
Compound 6 [ <del>SEQ. ID. NO. 10</del> ] ( <u>SEQ ID NO: 10</u> )	59.05
Compound 7 [ <del>SEQ. ID. NO. 11</del> ] ( <u>SEQ ID NO: 11</u> )	5.44
Compound 8 [ <del>SEQ. ID. NO. 12</del> ] ( <u>SEQ ID NO: 12</u> )	1.75
Compound 9 [ <del>SEQ. ID. NO. 13</del> ] ( <u>SEQ ID NO: 13</u> )	0.88
Compound 10 [ <del>SEQ. ID. NO. 14</del> ] ( <u>SEQ ID NO: 14</u> )	1.96
Compound 11 [ <del>SEQ. ID. NO. 15</del> ] ( <u>SEQ ID NO: 15</u> )	0.69
Compound 12 [ <del>SEQ. ID. NO. 16</del> ] ( <u>SEQ ID NO: 16</u> )	2.94
Compound 13 [ <del>SEQ. ID. NO. 17</del> ] ( <u>SEQ ID NO: 17</u> )	7.82
Compound 14 [ <del>SEQ. ID. NO. 18</del> ] ( <u>SEQ ID NO: 18</u> )	0.04
Compound 15 [ <del>SEQ. ID. NO. 19</del> ] ( <u>SEQ ID NO: 19</u> )	0.48

USSN 09/554,533  
Atty Docket No. 238/086US

Compound 16 <del>{SEQ. ID. NO. 20}</del> (SEQ ID NO: 20)	1.10
Compound 17 <del>{SEQ. ID. NO. 21}</del> (SEQ ID NO: 21)	21.6
Compound 18 <del>{SEQ. ID. NO. 22}</del> (SEQ ID NO: 22)	0.63
Compound 19 <del>{SEQ. ID. NO. 23}</del> (SEQ ID NO: 23)	0.63
Compound 20 <del>{SEQ. ID. NO. 24}</del> (SEQ ID NO: 24)	0.94
Compound 21 <del>{SEQ. ID. NO. 25}</del> (SEQ ID NO: 25)	9.91
Compound 22 <del>{SEQ. ID. NO. 26}</del> (SEQ ID NO: 26)	8.24
Compound 23 <del>{SEQ. ID. NO. 27}</del> (SEQ ID NO: 27)	0.82

Page 81, Table II (lines 1-26): Please replace Table II with the following:

**TABLE II**

<u>Compound</u>	<u>EC<sub>50</sub> (nM)</u>
Exendin-4 <del>{SEQ. ID. NO. 2}</del> (SEQ ID NO: 2)	0.23
Compound 1 <del>{SEQ. ID. NO. 5}</del> (SEQ ID NO: 5)	0.3
Compound 2 <del>{SEQ. ID. NO. 6}</del> (SEQ ID NO: 6)	0.79
Compound 3 <del>{SEQ. ID. NO. 7}</del> (SEQ ID NO: 7)	2.35
Compound 4 <del>{SEQ. ID. NO. 8}</del> (SEQ ID NO: 8)	0.22
Compound 5 <del>{SEQ. ID. NO. 9}</del> (SEQ ID NO: 9)	9.85
Compound 6 <del>{SEQ. ID. NO. 10}</del> (SEQ ID NO: 10)	79.4
Compound 7 <del>{SEQ. ID. NO. 11}</del> (SEQ ID NO: 11)	63.6
Compound 8 <del>{SEQ. ID. NO. 12}</del> (SEQ ID NO: 12)	6.8
Compound 9 <del>{SEQ. ID. NO. 13}</del> (SEQ ID NO: 13)	1.68
Compound 10 <del>{SEQ. ID. NO. 14}</del> (SEQ ID NO: 14)	5.37
Compound 11 <del>{SEQ. ID. NO. 15}</del> (SEQ ID NO: 15)	0.48
Compound 12 <del>{SEQ. ID. NO. 16}</del> (SEQ ID NO: 16)	15.55
Compound 13 <del>{SEQ. ID. NO. 17}</del> (SEQ ID NO: 17)	79.6
Compound 14 <del>{SEQ. ID. NO. 18}</del> (SEQ ID NO: 18)	1.11
Compound 15 <del>{SEQ. ID. NO. 19}</del> (SEQ ID NO: 19)	1.05
Compound 16 <del>{SEQ. ID. NO. 20}</del> (SEQ ID NO: 20)	5.12

USSN 09/554,533  
Atty Docket No. 238/086US

Compound 17 <del>{SEQ. ID. NO. 21}</del> (SEQ ID NO: 21)	43.6
Compound 18 <del>{SEQ. ID. NO. 22}</del> (SEQ ID NO: 22)	0.76
Compound 19 <del>{SEQ. ID. NO. 23}</del> (SEQ ID NO: 23)	3.68
Compound 20 <del>{SEQ. ID. NO. 24}</del> (SEQ ID NO: 24)	5.25
Compound 21 <del>{SEQ. ID. NO. 25}</del> (SEQ ID NO: 25)	45.1
Compound 22 <del>{SEQ. ID. NO. 26}</del> (SEQ ID NO: 26)	20.43
Compound 23 <del>{SEQ. ID. NO. 27}</del> (SEQ ID NO: 27)	3.05

Page 83, Table III (lines 1-26): Please replace Table III with the following:

**TABLE III**

<u>Test Compound</u>	<u>% drop in glucose</u>
Exendin-4 <del>{SEQ. ID. NO. 2}</del> (SEQ ID NO: 2)	39% (n = 78)
Compound 2 <del>{SEQ. ID. NO. 6}</del> (SEQ ID NO: 6)	38% (n = 4)
Compound 3 <del>{SEQ. ID. NO. 7}</del> (SEQ ID NO: 7)	49% (n = 4)
Compound 4 <del>{SEQ. ID. NO. 8}</del> (SEQ ID NO: 8)	27% (n = 4)
Compound 5 <del>{SEQ. ID. NO. 9}</del> (SEQ ID NO: 9)	47% (n = 4)
Compound 6 <del>{SEQ. ID. NO. 10}</del> (SEQ ID NO: 10)	40% (n = 5)
Compound 7 <del>{SEQ. ID. NO. 11}</del> (SEQ ID NO: 11)	31% (n = 4)
Compound 8 <del>{SEQ. ID. NO. 12}</del> (SEQ ID NO: 12)	44% (n = 4)
Compound 9 <del>{SEQ. ID. NO. 13}</del> (SEQ ID NO: 13)	41% (n = 4)
Compound 10 <del>{SEQ. ID. NO. 14}</del> (SEQ ID NO: 14)	46% (n = 4)
Compound 11 <del>{SEQ. ID. NO. 15}</del> (SEQ ID NO: 15)	40% (n = 4)
Compound 12 <del>{SEQ. ID. NO. 16}</del> (SEQ ID NO: 16)	53% (n = 4)
Compound 13 <del>{SEQ. ID. NO. 17}</del> (SEQ ID NO: 17)	45% (n = 4)
Compound 14 <del>{SEQ. ID. NO. 18}</del> (SEQ ID NO: 18)	54% (n = 4)
Compound 15 <del>{SEQ. ID. NO. 19}</del> (SEQ ID NO: 19)	45% (n = 4)
Compound 16 <del>{SEQ. ID. NO. 20}</del> (SEQ ID NO: 20)	54% (n = 4)
Compound 17 <del>{SEQ. ID. NO. 21}</del> (SEQ ID NO: 21)	45% (n = 4)
Compound 18 <del>{SEQ. ID. NO. 22}</del> (SEQ ID NO: 22)	50% (n = 4)

USSN 09/554,533  
Atty Docket No. 238/086US

Compound 19 <del>{SEQ. ID. NO. 23}</del> (SEQ ID NO: 23)	48%	(n = 4)
Compound 20 <del>{SEQ. ID. NO. 24}</del> (SEQ ID NO: 24)	37%	(n = 4)
Compound 21 <del>{SEQ. ID. NO. 25}</del> (SEQ ID NO: 25)	30%	(n = 4)
Compound 22 <del>{SEQ. ID. NO. 26}</del> (SEQ ID NO: 26)	46%	(n = 4)
Compound 23 <del>{SEQ. ID. NO. 27}</del> (SEQ ID NO: 27)	42%	(n = 4)

**Page 84, fourth full paragraph (lines 22-25):** Please replace the paragraph with the following:

Figure 5 depicts the effects of varying doses of exendin-4 ~~{SEQ. ID. NO. 2}~~ (SEQ ID NO: 2) and Compound 3 ~~{SEQ. ID. NO. 7}~~ (SEQ ID NO: 7) on plasma glucose levels. Exendin-4 had an ED<sub>50</sub> of 0.01 µg per mouse and Compound 3 had an ED<sub>50</sub> of 0.04 µg per mouse.

**Page 85, first full paragraph (lines 3-11):** Please replace the paragraph with the following:

Male Harlan Sprague Dawley (HSD) rats were used. All animals were housed at 22.7 ± 0.8 °C in a 12:12 hour light:dark cycle (experiments being performed during the light cycle) and were fed and watered *ad libitum* (Diet LM-485, Teklad, Madison, WI). Exendin-4 was synthesized according to standard peptide synthesis methods. The preparation of Compounds 2, 3, 10 and 13 ~~{SEQ. ID. NOS. 6, 7, 14 and 17}~~ (SEQ ID NOS: 6, 7, 14 and 17) is described in Examples 2, 3, 10 and 13, respectively.

**Page 86, first full paragraph (lines 5-9):** Please replace the paragraph with the following:

In baseline studies, with no drug treatment, gastric emptying over 20 min was determined. In dose-response studies, rats were treated with 0.01, 0.1, 0.3, 1, 10 and 100 µg of exendin-4, and 0.1, 0.3, 1, 10 and 100 µg of Compounds 2, 3, 10 and 13 ~~{SEQ. ID. NOS. 6, 7, 14 and 17}~~ (SEQ ID NOS: 6, 7, 14 and 17).